Cargando…

Hypofibrinogenemia following injury in 186 children and adolescents: identification of the phenotype, current outcomes, and potential for intervention

OBJECTIVES: Recent studies evaluating fibrinogen replacement in trauma, along with newly available fibrinogen-based products, has led to an increase in debate on where products such as cryoprecipitate belong in our resuscitation strategies. We set out to define the phenotype and outcomes of those wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerard, Justin, Van Gent, Jan-Michael, Cardenas, Jessica, Gage, Christian, Meyer, David E, Cox, Charles, Wade, Charles E, Cotton, Bryan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649809/
https://www.ncbi.nlm.nih.gov/pubmed/38020863
http://dx.doi.org/10.1136/tsaco-2023-001108
_version_ 1785135635698286592
author Gerard, Justin
Van Gent, Jan-Michael
Cardenas, Jessica
Gage, Christian
Meyer, David E
Cox, Charles
Wade, Charles E
Cotton, Bryan A
author_facet Gerard, Justin
Van Gent, Jan-Michael
Cardenas, Jessica
Gage, Christian
Meyer, David E
Cox, Charles
Wade, Charles E
Cotton, Bryan A
author_sort Gerard, Justin
collection PubMed
description OBJECTIVES: Recent studies evaluating fibrinogen replacement in trauma, along with newly available fibrinogen-based products, has led to an increase in debate on where products such as cryoprecipitate belong in our resuscitation strategies. We set out to define the phenotype and outcomes of those with hypofibrinogenemia and evaluate whether fibrinogen replacement should have a role in the initial administration of massive transfusion. METHODS: All patients <18 years of age presenting to our trauma center 11/17–4/21 were reviewed. We then evaluated all patients who received emergency-release and massive transfusion protocol (MTP) products. Patients were defined as hypofibrinogenemic (HYPOFIB) if admission fibrinogen <150 or rapid thrombelastography (r-TEG) angle <60 degrees. Our analysis sought to define risk factors for presenting with HYPOFIB, the impact on outcomes, and whether early replacement improved mortality. RESULTS: 4169 patients were entered into the trauma registry, with 926 level 1 trauma activations, of which 186 patients received emergency-release blood products during this time; 1%, 3%, and 10% were HYPOFIB, respectively. Of the 186 patients of interest, 18 were HYPOFIB and 168 were non-HYPOFIB. The HYPOFIB patients were significantly younger, had lower field and arrival Glasgow Coma Scale, had higher head Abbreviated Injury Scale, arrived with worse global coagulopathy, and died from brain injury. Non-HYPOFIB patients were more likely to have (+)focused assessment for the sonography of trauma on arrival, sustained severe abdominal injuries, and die from hemorrhage. 12% of patients who received early cryoprecipitate (0–2 hours) had higher mortality by univariate analysis (55% vs 31%, p=0.045), but no difference on multivariate analysis (OR 0.36, 95% CI 0.07 to 1.81, p=0.221). Those receiving early cryoprecipitate who survived after pediatric intensive care unit (PICU) admission had lower PICU fibrinogen and r-TEG alpha-angle values. CONCLUSION: In pediatric trauma, patients with hypofibrinogenemia on admission are most likely younger and to have sustained severe brain injury, with an associated mortality of over 80%. Given the absence of bleeding-related deaths in HYPOFIB patients, this study does not provide evidence for the empiric use of cryoprecipitate in the initial administration of a massive transfusion protocol. LEVEL OF EVIDENCE: Level III - Therapeutic/Care Management.
format Online
Article
Text
id pubmed-10649809
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-106498092023-11-09 Hypofibrinogenemia following injury in 186 children and adolescents: identification of the phenotype, current outcomes, and potential for intervention Gerard, Justin Van Gent, Jan-Michael Cardenas, Jessica Gage, Christian Meyer, David E Cox, Charles Wade, Charles E Cotton, Bryan A Trauma Surg Acute Care Open Original Research OBJECTIVES: Recent studies evaluating fibrinogen replacement in trauma, along with newly available fibrinogen-based products, has led to an increase in debate on where products such as cryoprecipitate belong in our resuscitation strategies. We set out to define the phenotype and outcomes of those with hypofibrinogenemia and evaluate whether fibrinogen replacement should have a role in the initial administration of massive transfusion. METHODS: All patients <18 years of age presenting to our trauma center 11/17–4/21 were reviewed. We then evaluated all patients who received emergency-release and massive transfusion protocol (MTP) products. Patients were defined as hypofibrinogenemic (HYPOFIB) if admission fibrinogen <150 or rapid thrombelastography (r-TEG) angle <60 degrees. Our analysis sought to define risk factors for presenting with HYPOFIB, the impact on outcomes, and whether early replacement improved mortality. RESULTS: 4169 patients were entered into the trauma registry, with 926 level 1 trauma activations, of which 186 patients received emergency-release blood products during this time; 1%, 3%, and 10% were HYPOFIB, respectively. Of the 186 patients of interest, 18 were HYPOFIB and 168 were non-HYPOFIB. The HYPOFIB patients were significantly younger, had lower field and arrival Glasgow Coma Scale, had higher head Abbreviated Injury Scale, arrived with worse global coagulopathy, and died from brain injury. Non-HYPOFIB patients were more likely to have (+)focused assessment for the sonography of trauma on arrival, sustained severe abdominal injuries, and die from hemorrhage. 12% of patients who received early cryoprecipitate (0–2 hours) had higher mortality by univariate analysis (55% vs 31%, p=0.045), but no difference on multivariate analysis (OR 0.36, 95% CI 0.07 to 1.81, p=0.221). Those receiving early cryoprecipitate who survived after pediatric intensive care unit (PICU) admission had lower PICU fibrinogen and r-TEG alpha-angle values. CONCLUSION: In pediatric trauma, patients with hypofibrinogenemia on admission are most likely younger and to have sustained severe brain injury, with an associated mortality of over 80%. Given the absence of bleeding-related deaths in HYPOFIB patients, this study does not provide evidence for the empiric use of cryoprecipitate in the initial administration of a massive transfusion protocol. LEVEL OF EVIDENCE: Level III - Therapeutic/Care Management. BMJ Publishing Group 2023-11-09 /pmc/articles/PMC10649809/ /pubmed/38020863 http://dx.doi.org/10.1136/tsaco-2023-001108 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Gerard, Justin
Van Gent, Jan-Michael
Cardenas, Jessica
Gage, Christian
Meyer, David E
Cox, Charles
Wade, Charles E
Cotton, Bryan A
Hypofibrinogenemia following injury in 186 children and adolescents: identification of the phenotype, current outcomes, and potential for intervention
title Hypofibrinogenemia following injury in 186 children and adolescents: identification of the phenotype, current outcomes, and potential for intervention
title_full Hypofibrinogenemia following injury in 186 children and adolescents: identification of the phenotype, current outcomes, and potential for intervention
title_fullStr Hypofibrinogenemia following injury in 186 children and adolescents: identification of the phenotype, current outcomes, and potential for intervention
title_full_unstemmed Hypofibrinogenemia following injury in 186 children and adolescents: identification of the phenotype, current outcomes, and potential for intervention
title_short Hypofibrinogenemia following injury in 186 children and adolescents: identification of the phenotype, current outcomes, and potential for intervention
title_sort hypofibrinogenemia following injury in 186 children and adolescents: identification of the phenotype, current outcomes, and potential for intervention
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649809/
https://www.ncbi.nlm.nih.gov/pubmed/38020863
http://dx.doi.org/10.1136/tsaco-2023-001108
work_keys_str_mv AT gerardjustin hypofibrinogenemiafollowinginjuryin186childrenandadolescentsidentificationofthephenotypecurrentoutcomesandpotentialforintervention
AT vangentjanmichael hypofibrinogenemiafollowinginjuryin186childrenandadolescentsidentificationofthephenotypecurrentoutcomesandpotentialforintervention
AT cardenasjessica hypofibrinogenemiafollowinginjuryin186childrenandadolescentsidentificationofthephenotypecurrentoutcomesandpotentialforintervention
AT gagechristian hypofibrinogenemiafollowinginjuryin186childrenandadolescentsidentificationofthephenotypecurrentoutcomesandpotentialforintervention
AT meyerdavide hypofibrinogenemiafollowinginjuryin186childrenandadolescentsidentificationofthephenotypecurrentoutcomesandpotentialforintervention
AT coxcharles hypofibrinogenemiafollowinginjuryin186childrenandadolescentsidentificationofthephenotypecurrentoutcomesandpotentialforintervention
AT wadecharlese hypofibrinogenemiafollowinginjuryin186childrenandadolescentsidentificationofthephenotypecurrentoutcomesandpotentialforintervention
AT cottonbryana hypofibrinogenemiafollowinginjuryin186childrenandadolescentsidentificationofthephenotypecurrentoutcomesandpotentialforintervention